1 Research grants; 2 Consulting fees; 3 Employee; 4 Speakers bureau; 5 Stocks, stock options, or bond holdings.
|
|
- Magnus Clark
- 5 years ago
- Views:
Transcription
1 Screening & Randomization 11/7/ Disclosures: This study was funded by Roche Efficacy and Safety of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis: 2-Year Data From a Phase III Clinical Trial F. De Benedetti, H Brunner, N. Ruperto, A Kenwright, C. Devlin, I. Calvo, R. Cuttica, A. Ravelli, R Schneider, D. Eleftheriou, C. Wouters, R. Xavier, L. Zemel, E. Baildam, R. Burgos-Vargas, P. Dolezalova, S. M. Garay, R. Joos, A. Grom, N. Wulffraat, Z. Zuber, F. Zulian,. A. Martini, D. Lovell The authors disclose the following financial relationships: F. De Benedetti (All funds go to the children Hospital): Abbott, 1 BMS, 1,2 Pfizer, 1,2 SOBI, 1 Novimmune, 1 Roche, 1,2 Novartis 1 H. Brunner (all funds go to Cincinnati Children s Hospital): Amgen, 2 Bristol-Meyers Squibb, 1 Abbott, 1 Pfizer, 2 Roche, 2 Novartis, 2 UBC 2 N. Ruperto (all funds go to Gaslini Children s Hospital): BMS, 1,4 Abbott, 1 Novartis, 1 Roche, 1,4 Centocor, 1 ACRAF, 1 Pfizer, 1 Xoma 1 A. Kenwright: Roche,4 C. Devlin: Roche,4 I. Calvo: None R. Cuttica: None A. Ravelli: None R. Schneider: Roche, 2 Innomar Strategies 2 D. Eleftheriou: None C Wouters: GSK 1 R. Xavier: Roche, 1,2,4 Pfizer, 1,2,4 Janssen 2,4 L. Zemel: None E. Baildam: None R. Burgos-Vargas: Abbot, 2, BMS, 2, MSD, 2, Pfizer, 2, Roche 1,2, P. Dolezalova: None S. M. Garay: None R. Joos: None A. Grom: Novartis 2 N. Wulffraat: None Z. Zuber: None F. Zulian: None A. Martini (all funds go to Gaslini Children s Hospital): BMS, 1,4 Abbott, 1 Novartis, 1,2 Roche, 1,2 Centocor, 1 ACRAF, 1 Pfizer, 1 Xoma 1 D. Lovell (all funds go to Cincinnati Children s Hospital): Astra-Zeneca, 2 Wyeth, 2 Amgen, 2 BMS, 1 Abbott, 1 Pfizer, 2 Regneron, 2 Roche, 2 Novartis, 2 UBC, 2 Xoma 2 1 Research grants; 2 Consulting fees; Employee; 4 Speakers bureau; Stocks, stock options, or bond holdings. Evidence-Based Medicine (EBM) TENDER: 12-Week Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, 2-Arm Study (Part I) with Single- Arm, Open-label Extension (Parts II and III) Years in Total 4 Woo P, Wilkinson N, Prieur AM, et al. Open-label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2;7:R1281-R1288. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 28;71: De Benedetti F, Brunner H, Ruperto N, et al. Efficacy and safety of tocilizumab (TCZ) in patients (pts) with systemic juvenile idiopathic arthritis (sjia): TENDER 2-week data. Presented at EULAR 211. Ann Rheum Dis 211;7(Suppl):67 Study Design Double-Blind Period (Part I) 7 pts 7 pts TCZ 8 or 12 mg/kg a x 6 Placebo x Week Day Escape with rescue therapy Open-Label Period (Parts II - III) TCZ 8 or 12 mg/kg a every 2 weeks for 92 weeks (subsequent -year extension added) a 8 mg/kg if body weight kg; 12 mg/kg if body weight < kg. TENDER: Key Inclusion Criteria TENDER: Demographic and Baseline Characteristics 6 Diagnosis of sjia according to ILAR criteria Age 2 17 years Persistent disease activity for 6 months, with an inadequate response to corticosteroids and NSAIDs due to toxicity or lack of efficacy active joints OR 2 active joints with fever >8 C Maximum dose of oral corticosteroids:. mg/kg/day (prednisone equivalent) Stable dose of oral corticosteroids, MTX, and/or NSAIDs No other DMARDs or biologic allowed N = 112 Age (y), mean (SD) 9.7 (4.6) Disease duration (y), mean (SD).2 (4.1) Previous DMARDs use, n (%) 82 (7) Previous TNF inhibitor use, n (%) 81 (72) Previous IL-1 inhibitor use, n (%) 4 (48) Physician VAS, mean (SD) 64.9 (22.) Parent/patient VAS, mean (SD) 8.7 (24.4) Number of active joints, mean (SD) 19.8 (1.7) Number of joints with LOM, mean (SD) 19.8 (1.6) ESR (mm/h) mean (SD) 7.6 (4.2) CHAQ-DI, mean (SD) 1.7 (.9) CRP (mg/l), mean (SD) (49.24) Fever (last 7 days), n (%) 48 (4) Background oral corticosteroid dose, (mg/kg/day PDN eq), mean (SD). (.2) Re-baselined at the first dose of TCZ. 1
2 Double-blind Baseline to Week 12 Open-label Mean (SE) CHAQ-DI 11/7/211 TENDER: Efficacy in Double-Blind Phase JIA ACR + Absence of Fever at Week 12 JIA ACR /7/9 Responses at Week 12 7 TENDER Patient Disposition Placebo n=7 Screened N=126 Enrolled N=112 Tocilizumab n= % (9% CI: )*, Placebo (n=7) n=9 n= Placebo TCZ TCZ (n=7) JIA JIA JIA (n=7) (n=7) ACR ACR7 ACR9 *Weighted difference. p<.1 Cochran-Mantel-Haenszel analysis adjusted for randomization stratification factors applied at baseline TCZ (n=7) Completed Escaped Completed Escaped a Withdrew 17 (46%) 2 (4%) 72 (96%) 2 (%) Fever AE 1 (27%) JIA ACR Refused Tx Flare 9 (24%) Other c 1 (%) AE Enrolled in Open-Label Extension Phase N=11 Death Withdrew 18 Response Ongoing N=92 Other b a 1 patient in the TCZ group received escape therapy on study day 1; the investigator initially suspected MAS, which was later determined to be liver function test elevations. b patients refused treatment, and 1 patient did not return. c Patient was initially suspected to have MAS, which was later determined to be an sjia flare. TENDER: Analyses of 14-Week Data Baseline Patients randomized to TCZ day 1 Patients randomized to placebo were re-baselined at the first TCZ dose Endpoints Durability and magnitude of TCZ efficacy response Effect of TCZ to reduce or eliminate oral corticosteroids Safety of TCZ in chronic administration Analysis population 61 patients received at least 14 weeks of TCZ treatment Patients who withdrew because of insufficient therapeutic response before week 14 were included and considered nonresponders (n=) for JIA ACR responses Patients who withdrew for nonefficacy-related reasons were excluded (n=1 [9 safety and 6 other]) for JIA ACR responses 9 JIA ACR Responses Over Time JIA ACR JIA ACR JIA ACR JIA ACR9 n = Percentage is based on number of patients who reached time point + patients who withdrew because of insufficient therapeutic response and are assumed to have been nonresponders. 1 No Active Joints and Inactive Disease Over Time No Active Joints Inactive Disease Physical Function Over Time No Joints with limitation CHAQ-DI score b of movement a. 2. CHAQ-DI >.7 Baseline: 82.1% 2. Week 14: 4.7% a Patients who withdrew because of insufficient therapeutic response are assumed to be nonresponders. b Patients who withdrew are excluded. 12 2
3 Mean (SE) Dose 11/7/211 Mean Oral Corticosteroid Dose Over Time 1 Cumulative Safety % discontinued CS by week 14 Mean dose decreased to.4 mg/kg/day Patients who withdrew have been excluded at postwithdrawal visits.. Prior Safety Update a Week 14 b Exposure to TCZ, y Rate of SAEs/1PY (n) 24.8 (9) 2. (47) Rate of infections/1py (n).6 (4) (7) Rate of serious infection AEs/1PY (n) 11.4 (18) 1.9 (22) SAEs related (remotely, possibly, probably) to TCZ/1 PY (n) 8. (1) 7.4 (1) Macrophage activation syndrome/1py (n) 1.9 () 1. () AEs leading to withdrawal/1py (n).8 (6) c. (6) c Deaths/1PY (n).6 (1) 1. () Pneumothorax 1 1 Sepsis (possibly related) 1 Road Traffic Accident 1 a Includes all safety data in the database up to and including August 1, 21. b Includes all safety data in the database up to the week 14 infusion (based on date of randomization) for each pt. The last date for this was May 1, 211. c Includes 2 withdrawals because of transaminase increases that were protocol mandated. 16 Deaths after discontinuation from TENDER Pat # Country 11* Netherlands 1611 Italy Event name Death of unknown cause Age at death 1 y mo. Atrioventricular 17 y block (in 9 mo. hyperkalaemia) 164 Italy Cardiac arrest 18 y 7 mo. Date of Death (duration from last TCZ dose) July-1 (6 mo.) Dec-11-1 (1 y 1 mo.) Duration of TCZ tx Date of last TCZ dose wks Jan-21-1 Reason for withdrawal from TENDER therapeutic response AE - Pulmonary 4 wks Nov-18-9 venoocclusive disease Apr-1-11 (1 y 2 mo.) 48 wks Feb-1-1 therapeutic response Most Common* Serious Adverse Events Event, n (%) N = 112 Varicella 4 (.6) Gastroenteritis 4 (.6) Macrophage activation syndrome (2.7) Pneumonia (2.7) Dehydration 2 (1.8) Herpes zoster 2 (1.8) * Patient 11 entered another biologic study April 21. *Preferred terms with incidence > 1 patient 18 TENDER: Clinical Laboratory Evaluations Grade a No. (%) Neutrophils (-<1, cells/mm ) 26 (2.2) 4 (< cells/mm ) 2 (1.8) b Platelets (2,-<, cells/mm ) 1 (.9) c 4 (<2, cells/mm ) ALT (>-2 x ULN) 9 (8.) 4 (>2 x ULN) 1 (.9) c Conclusions TENDER 2-year results demonstrated sustained efficacy and no change in the safety profile during long-term TCZ treatment Responses occurred early and were maintained over time 6% of patients who received 14 weeks of TCZ were able to discontinue oral corticosteroids 7% in inactive disease status by week 14 a Common Toxicity Criteria Vers. Grades. b Both single occurrences, returned to normal no associated infection. c Platelet decrease and ALT increase occurred during MAS.
4 11/7/ Argentina Cuttica Espada Garay Australia Allen Chaitow Murray Belgium Joos Wouters Brazil Silva Xavier Canada Roth Schneider Czech Republic Dolezalova Germany Horneff Huppertz Minden Greece Mantzourani Siammopoulou Vougiouka Italy Cortis Gerloni Martini Zulian Mexico Burgos Maldonado Netherlands Norway Poland Slovakia Wulffraat Flato Zuber Rovensky Spain Calvo Garcia Consuegra UK Baildam Woo USA Investigators 4 centers from 17 countries Brown Chalom Jerath Kimura Lovell Myones O'Neill Onel Spalding Zemel Back-up Infections N = 112 Infections and infestations/1 PY (7) Serious infection AEs/1 PY (n) 1.9 (22) Infections (remotely, possibly, probably) related to study treatment 8 Gastroenteritis 1 Otitis media 1 Pharyngotonsillitis 1 Septic arthritis 1 Streptococcal sepsis 1 Tonsillitis 1 Upper respiratory infection 1 Varicella 1 TENDER: Oral Corticosteroid Tapering Allowed if ESR <2 mm/hr and In double-blind phase at weeks 6 and 8 (not at week 1) If absence of fever and JIA ACR7 In open-label extension phase (not at weeks 24,, 76, and 12) If absence of fever and JIA ACR Not permitted more frequently than every 2 weeks Maximum tapering allowed: 2% of current (last visit) dose in double-blind phase and at investigator s discretion in open-label JIA ACR Responses Over Time JIA ACR and absence of fever JIA ACR 2 JIA ACR JIA ACR7 JIA ACR n = Percentage is based on number of patients who reached time point + patients who withdrew because 2 No Active Joints and No Joints With Limitation Of Movement Over Time No Active Joints No Joints with limitation of movement n =
5 Mean (SE) Number of Active Joints 11/7/211 Physician Global Assessment VAS 1 mm 1 2 Patient/Parent Global Assessment VAS 1 mm n = n = Active Joint Count Over Time n = Percentage is based on number of patients who reached time point + patients who withdrew are excluded.
11/11/2012. Disclosures. Systemic Juvenile Idiopathic Arthritis Growth Defect. Chronic Inflammation and Stunted Growth
// Catch-up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: -Year Data From a Phase 3 Clinical Trial Fabrizio De Benedetti, Nicolino Ruperto, Graciela Espada, Valeria Gerloni,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing
More information11/7/2011. Disclosures
11/7/11 Efficacy & Safety of, a Fully Human Selective Anti-IL-1β Antibody, In Active Systemic Juvenile Idiopathic Arthritis Results From Two Phase III Studies Disclosures This study was sponsored by Novartis
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationCharité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3
Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-blind, Monotherapy Study in Patients With Active Rheumatoid Arthritis With Intolerance or Inadequate Response to Methotrexate
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationKeywords Biologicals. Juvenile idiopathic arthritis. Tocilizumab. Treatment ORIGINAL ARTICLE
Clinical Rheumatology (2018) 37:1807 1816 https://doi.org/10.1007/s10067-018-4071-9 ORIGINAL ARTICLE Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationUniversity of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
More information10/28/2013. Disclosures. Objectives. Background. Study Design. Key Inclusion Criteria
Randomization (1:1:1:1) /28/13 Tocilizumab in Combination Therapy and Monotherapy Versus Methotrexate in Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes
More informationSYNOPSIS. Clinical Study Report IM Double-blind Period
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority
More information2.0 Synopsis. Adalimumab M Clinical Study Report Final R&D/15/1093. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationSynopsis (C0524T12 GO LIVE)
Protocol: EudraCT No.: 2005-003232-21 Title of the study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Intravenously,
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationAdalimumab M Clinical Study Report Final R&D/14/1263. Page:
Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Study:
More informationGuideline Update: 2013 ACR Recommendations Norman T. Ilowite, MD
Guideline Update: 2013 ACR Recommendations Norman T. Ilowite, MD Professor of Pediatrics Albert Einstein College of Medicine Bronx, NY Introduction Recommendations always intended to be reviewed annually
More informationStudy synopsis of the global non-interventional study SWITCH-RA
Study synopsis of the global non-interventional study SWITCH-RA Protocol number: MA22401 Title of Study: A global multi-centre observational study in RA patients who are non-responders or intolerant to
More informationRoACTEMRA for Systemic Juvenile Idiopathic Arthritis (sjia)
RoACTEMRA for Systemic Juvenile Idiopathic Arthritis (sjia) HEALTHCARE PROFESSIONAL BROCHURE IMPORTANT EFFICACY AND SAFETY INFORMATION To assist healthcare professionals in assessing the benefits and risks
More informationManagement of patients on tocilizumab in daily practic. Evidence Based Medicine Official recommendations Expert opinion
S90 Tables Evidence Based Medicine Official recommendations Expert opinion Table 1: Examples of drugs that are metabolized by the cytochrome P450 isoenzymes The full list is available online at http://medicine.iupui.edu/clinpharm/ddis.
More informationClinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis
For reprint orders, please contact reprints@expert-reviews.com Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis Expert Rev. Clin. Pharmacol. 6(2), 123 137
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A
More informationIndividual Study Table Referring to Part of Dossier: Use Only) Name of Study Drug:
2.0 Synopsis AbbVie Inc. Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Adalimumab (Humira ) Page: Name of Active Ingredient: Adalimumab
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationTechnology appraisal guidance Published: 14 December 2011 nice.org.uk/guidance/ta238
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis Technology appraisal guidance Published: 14 December 2011 nice.org.uk/guidance/ta238 NICE 2018. All rights reserved. Subject to Notice
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationExtended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA;
1 Denver Arthritis Clinic, Denver, Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; 3 Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; 4 Arthritis &
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationPharmacy Medical Necessity Guidelines: Actemra (tocilizumab)
Pharmacy Medical Necessity Guidelines: Effective: July 11, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or Medical
More informationKenneth W. Mahaffey, MD and Keith AA Fox, MB ChB
Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf
More informationACTEMRA Risk Mitigation Strategy Presenter Name, Degree
ACTEMRA Risk Mitigation Strategy Presenter Name, Degree Medical Science Liaison Genentech, Inc. 1 Indications and Dosage Rheumatoid Arthritis (RA) (1 of 2) Indication in RA ACTEMRA (tocilizumab) is indicated
More informationSynopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier
Module 5.3 Protocol: EudraCT No.: 2005-003525-92 Title of the study: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered
More informationAdalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis
The new england journal of medicine original article Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis Daniel J. Lovell, M.D., M.P.H., Nicolino Ruperto, M.D., M.P.H., Steven Goodman,
More informationTocilizumab for the treatment of systemic juvenile idiopathic arthritis
in collaboration with: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis Produced by Authors Correspondence to Kleijnen Systematic Reviews Ltd. in collaboration with Erasmus University
More informationTechnology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta373
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta373 NICE 2017. All rights reserved.
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Eisai Co., Ltd Name of Study Drug: Humira 40 mg/ 0.8 ml (To be determined for 20 mg product) Humira 20 mg/ 0.4 ml (To be determined for 20 mg product) Name of Active Ingredient:
More informationTitle: Predictive factors of relapse, in patients with JIA in remission, after discontinuation of synthetic disease-modifying antirheumatic drugs.
Title: Predictive factors of relapse, in patients with JIA in remission, after discontinuation of synthetic disease-modifying antirheumatic drugs. Background Juvenile idiopathic arthritis (JIA) is not
More informationExtended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA;
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate
More informationgolimumab Principal Investigator(s): Principal Investigator: Michael E. Weinblatt, MD Brigham and Women s
Module 5.3.5.1 Rheumatoid Arthritis IV (24-Week submission) 24-Week CNTO148ART3001Clinical Study Report SYNOPSIS Issue Date: 07 Nov 2011 Document No.: EDMS-ERI-22836553 Name of Sponsor/Company Name of
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationBRIEFING DOCUMENT. human, recombinant fusion protein: extracellular domain of CTLA-4 and Fc domain of human IgG1
BRIEFING DOCUMENT Application Type BLA Submission Number 125118/0 Reviewer Name Team Leader Division Director Established Name (Proposed) Trade Name Applicant Formulation Dosing Regimen Indication Intended
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ruperto N, Martini A. Current and future perspectives
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationUNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS
UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS CanVasc meeting Montreal Nov 22 2012 Patrick Liang Service de rhumatologie Centre Hospitalier Universitaire
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT RoActemra 20 mg/ml concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml concentrate contains
More informationIndustry Relationships and Institutional Affiliations
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher
More informationDesign and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009
Design and Analysis of a Cancer Prevention Trial: Plans and Results Matthew Somerville 09 November 2009 Overview Objective: Review the planned analyses for a large prostate cancer prevention study and
More informationIL-6 Targeting. Arthur Kavanaugh: Disclosures. Abbott Amgen Astra-Zeneca Biogen-Idec BMS Celgene Centocor Genentech TREG Consultants LLC
IL-6 Targeting Arthur Kavanaugh, MD Professor of Medicine Division of Rheumatology, Allergy, and Immunology Director, Center for Innovative Therapy University of California San Diego La Jolla, CA Arthur
More informationStudy Number CAIN457C2302 (core study) and CAIN457C2302E1 (extension study)
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Uveitis Approved Indication Investigational Study Number CC2302 (core study) and CC2302E1
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationRegulatory Status FDA-approved indication: Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Section: Prescription Drugs Effective Date: Oct 1, 2016 Subject: Enbrel Page: 1 of 7 Last Review Date:
More informationAmerican College of Rheumatology Analyst and Investor Meeting November 6, 2011
American College of Rheumatology 2011 Analyst and Investor Meeting November 6, 2011 Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements Our discussions during this meeting
More informationTARGET Clinical Trial Identifier: NCT American College of Rheumatology Annual Meeting; November 7-11, 2015; San Francisco, CA
Efficacy and Safety of Sarilumab in Combination With csdmards in Patients With Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti-TNF Therapy: Results From a Phase 3 Study
More informationUniversity of Bristol - Explore Bristol Research. Peer reviewed version. Link to published version (if available): / X.
Sen, E. S., & Ramanan, A. V. (2016). Biologic drugs in pediatric rheumatology. International Journal of Rheumatic Diseases, 19(6), 533-535. https://doi.org/10.1111/1756-185x.12924 Peer reviewed version
More informationSYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS DRUG
SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS Anakinra Kineret 100mg/0.67mg pre-filled syringe For the treatment of systemic juvenile idiopathic arthritis in patients who meet the following criteria; Patient
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationExtended report. Clinical and epidemiological research. Key messages
Clinical and epidemiological research Handling editor Josef S Smolen Additional material is published online only. To view please visit the journal online (http:// dx. doi. org/ 10. 1136/ annrheumdis-
More informationSummary of Risk Minimization Measures
Table 6.1.4-1: Summary of Risk Minimization Measures Safety Concern Vaccination Hepatic and renal impairment Combination therapy Elderly Routine Risk Minimization Measures Specific subsection on vaccination
More informationWARNING: RISK OF SERIOUS INFECTIONS
RA PROGRESSION INTERRUPTED 1 DOSAGE AND ADMINISTRATION GUIDE No structural damage progression was observed at week 52 in 55.6% and in 47.8% of patients receiving KEVZARA 200 mg + MTX or 150 mg + MTX, compared
More informationMonoclonal Antibodies in the Management of Rheumatoid Arthritis Prof. John D. Isaacs
John D Isaacs Professor of Clinical Rheumatology Director, Wilson Horne Immunotherapy Centre Newcastle University, UK 1 Rheumatoid arthritis Targeting T-cells Targeting B-cells Costimulation blockade Novel
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationOverview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology
Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology Paediatric Rheumatology Expert Meeting, London 4 th December 29 Dr. Richard Veselý, Dr. Emma Sala Soriano Paediatric Investigation
More informationPros and Cons of Combination MTX+ Biologics vs Monotherapy with Biologics: the place of immunogenicity
Pros and Cons of Combination MTX+ Biologics vs Monotherapy with Biologics: the place of immunogenicity Daniel E Furst MD University of California in Los Angeles University of Washington University of Florence
More information11/5/2011. Disclosures. Key References. JAK Inhibitors. Tofacitinib(CP ): Phase 2 Studies
Disclosures KINASE INHIBITORS IN RA Michael E. Weinblatt, M.D. Dr. Weinblatt has been a consultant to the following companies involved in the JAK and SYK pathways in RA Pfizer Vertex Astellas Rigel Astra-Zeneca
More informationTHERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More information24-Week CNTO1275PSA3001 Clinical Study Report
24-Week CNTO1275PSA3001 Clinical Study Report SYNOPSIS Issue Date: 17 Jan 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, Inc Ustekinumab
More informationtocilizumab (Actemra )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationEMA EFPIA workshop Break-out session no. 2
EMA EFPIA workshop Break-out session no. 2 Case Study Title: Improvement of clinical benefit for a sub-group of pediatric systemic Juvenile Idiopathic Arthritis (sjia)) patients utilizing model-based dose
More informationThe Use of Methotrexate in Juvenile Idiopathic Arthritis: A Single Center Experience
HK J Paediatr (new series) 2006;11:191-198 The Use of Methotrexate in Juvenile Idiopathic Arthritis: A Single Center Experience PPW LEE, TL LEE, WHS WONG, YL LAU Abstract Key words In the recent decade,
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationSponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and
More informationClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationACTEMRA (tocilizumab)
ACTEMRA (tocilizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More information1.0 Abstract. Title. Keywords. Adalimumab, Rheumatoid Arthritis, Effectiveness, Safety. Rationale and Background
1.0 Abstract Title Assessment of the safety of adalimumab in rheumatoid arthritis (RA) patients showing rapid progression of structural damage of the joints, who have no prior history of treatment with
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. International co-ordinating investigator Redacted
Drug product: Drug substance(s): AZD6140 Document No.: D5130C00002 Edition No.: 01 Study code: D5130C00002 Date: 12 October 2005 SYNOPSIS A Double-blind, Double-dummy, Parallel Group Randomised Dose Confirmation
More informationNew Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis
New Evidence reports on presentations given at EULAR 2011 Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis Report on EULAR 2011 presentations Anti-TNF failure and response to rituximab
More informationDiscordance between physician s and parent s global assessments in juvenile idiopathic arthritis
Rheumatology 2007;46:141 145 Advance Access publication 16 June 2006 Discordance between physician s and parent s global assessments in juvenile idiopathic arthritis doi:10.1093/rheumatology/kel201 F.
More informationA.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
More informationENBREL (Etanercept) 25 mg and 50 mg powder for injection and water for injections
PRODUCT INFORMATION ENBREL Etanercept (rch) NAME OF THE MEDICINE ENBREL (Etanercept) 25 mg and 50 mg powder for injection and water for injections ENBREL (Etanercept) 25 mg and 50 mg solution for injection
More informationABSTRACT. Keywords: Africa; Efficacy; Etanercept; Maintenance therapy; Middle East; Rheumatoid arthritis ORIGINAL RESEARCH
Rheumatol Ther (2018) 5:149 158 https://doi.org/10.1007/s40744-018-0094-6 ORIGINAL RESEARCH Maintenance of Remission with Etanercept DMARD Combination Therapy Compared with DMARDs Alone in African and
More informationU of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-severe Crohn s Disease Refractory to Anti-TNFα: UNITI-1 WJ Sandborn 1,
More informationORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab
ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents ORENCIA demonstrated comparable
More informationEthnic Minority RA Consortium (EMRAC)
Ethnic Minority RA Consortium (EMRAC) Yusuf Yazıcı, MD Assistant Professor of Medicine, New York University School of Medicine Director, Seligman Center for Advanced Therapeutics & Behçet Syndrome Evaluation,
More informationAdalimumab M Clinical Study Report Final R&D/13/224
Diagnosis and Main Criteria for Inclusion: A parent or guardian had voluntarily signed and dated an informed consent form, approved by an institutional review board/independent ethics committee, after
More informationUse of tocilizumab in Juvenile Idiopathic Arthritis
S54 Use of tocilizumab in Juvenile Idiopathic Arthritis Evidence Based Medicine Official recommendations Expert opinion The data generated by clinical trials of tocilizumab in adults with rheumatoid arthritis
More informationTHE USE OF BIOLOGICS RESPONSE MODIFIERS IN POLYARTICULAR- COURSE JUVENILE IDIOPATHIC ARTHRITIS
The Hospital for Sick Children Technology Assessment at Sick Kids (TASK) THE USE OF BIOLOGICS RESPONSE MODIFIERS IN POLYARTICULAR- COURSE JUVENILE IDIOPATHIC ARTHRITIS Authors: Vania Costa, MSc Research
More informationSafety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
Clin Rheumatol (2014) 33:1433 1441 DOI 10.1007/s10067-014-2498-1 ORIGINAL ARTICLE Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016 ClinicalTrials.gov ID: NCT00595413 Study Identification Unique Protocol ID: 27905 Brief Title: Atacicept
More informationPediatric rheumatic diseases (PRDs) are rare
World Journal of Pediatrics Network in pediatric rheumatology: the example of the Pediatric Rheumatology International Trials Organization Nicolino Ruperto, Alberto Martini Genova, Italy 186 Background:
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information